SLC35A2 and thyroid gland carcinoma: It was revealed that the high expression of SLC35A2 and advanced clinical stages were highly relevant in 18 cancers, including STAD, PAAD, LUAD, KIRC, ESCA, BRCA, thyroid cancer (THCA), TGCT, READ, LUSC, KIRP, HNSC, ACC, SKCM, LIHC, kidney chromophobe (KICH), COAD, and BLCA (Supplementary Figure 6).